> top > projects > Inflammaging > docs > PubMed:23994795 > annotations
Inflammaging  

PubMed:23994795 JSONTXT 4 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-30 Sentence denotes Interferon α-targeted therapy.
T1 0-30 Sentence denotes Interferon α-targeted therapy.
T2 31-180 Sentence denotes Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components.
T2 31-180 Sentence denotes Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies to various cellular components.
T3 181-277 Sentence denotes Although many of therapies have shown great efficacy, they often associate with adverse effects.
T3 181-277 Sentence denotes Although many of therapies have shown great efficacy, they often associate with adverse effects.
T4 278-436 Sentence denotes The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE.
T4 278-436 Sentence denotes The development of safer therapies for SLE has led to recent emphasis on targeting selected pathways that can be important in the inflammatory process in SLE.
T5 437-559 Sentence denotes The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE.
T5 437-559 Sentence denotes The cytokine family of type I interferons (IFNs), and especially the IFNα subtypes, are implicated in pathogenesis of SLE.
T6 560-684 Sentence denotes Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE.
T6 560-684 Sentence denotes Genetic polymorphisms of several components of the IFN signaling pathway have been associated with an increased risk of SLE.
T7 685-781 Sentence denotes Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE.
T7 685-781 Sentence denotes Therefore, IFNα subtypes have been identified as a potential target for drug development in SLE.
T8 782-894 Sentence denotes There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001.
T8 782-894 Sentence denotes There have been developed three agents, IFNα-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001.
T9 895-1051 Sentence denotes They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor.
T9 895-1051 Sentence denotes They are anti-IFNα monoclonal antibodies that bind to and specifically neutralizes most IFNα subtypes, preventing signaling through the type I IFN receptor.
T10 1052-1136 Sentence denotes The safety and dose-proportional pharmacokinetics of those agents were demonstrated.
T10 1052-1136 Sentence denotes The safety and dose-proportional pharmacokinetics of those agents were demonstrated.
T11 1137-1215 Sentence denotes A larger study is currently ongoing, further safety profile will be evaluated.
T11 1137-1215 Sentence denotes A larger study is currently ongoing, further safety profile will be evaluated.
T12 1216-1360 Sentence denotes This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.
T12 1216-1360 Sentence denotes This review provides an update on the ongoing clinical trials of anti-IFNα therapy and the promise and obstacles in the use of biologics in SLE.